Recommendation for Dual Immunotherapy Reimbursement in Hepatocellular Carcinoma

Zorginstituut Nederland has issued guidance on dual immunotherapy reimbursement for durvalumab combined with tremelimumab in advanced liver cancer, recommending against inclusion in the basic package unless net costs after negotiations stay within those of atezolizumab plus bevacizumab. The assessment confirms equal clinical value to the existing standard while meeting legal requirements for established medical practice.

Equal Survival Benefit Confirmed

Network meta-analysis of the HIMALAYA and IMbrave150 trials shows no clinically meaningful overall survival difference between durvalumab-tremelimumab and atezolizumab-bevacizumab. Four-year data from HIMALAYA further indicate 21.1 percent survival with the dual regimen versus 11.6 percent with sorafenib, meeting the PASKWIL tail criterion.

Patient Profile and Current Treatment

Hepatocellular carcinoma mainly affects individuals with cirrhosis or chronic hepatitis B, with roughly 700 new Dutch cases each year and five-year survival below 20 percent. Atezolizumab plus bevacizumab remains first-line therapy, while sorafenib is reserved for patients with high bleeding risk.

Budget Impact Under Dual Immunotherapy Reimbursement

The analysis forecasts 28 patients starting durvalumab-tremelimumab by year three, producing list-price costs of 1.9 million euros that fall to a net 291,242 euros after substitution. Lower generic prices for bevacizumab and sorafenib mean the actual budget effect will likely exceed this projection.

Price Parity Requirement

Because the regimens show equal value, no formal cost-effectiveness review applies and the outcome hinges on achieving price parity with atezolizumab-bevacizumab. Successful negotiations would allow inclusion while protecting the sustainability of the basic package.